Target

PDL1

110 products, 113 indications

Indications
Advanced melanoma (19 products)
metastatic melanoma (12 products)
metastatic non-small cell lung cancer (9 products)
NSCLC (8 products)
Metastatic Castration-Resistant Prostate Cancer (7 products)
advanced non-squamous NSCLC (7 products)
Melanoma (6 products)
metastatic cutaneous melanoma (5 products)
Unresectable Melanoma (5 products)
Metastatic Cancer (4 products)
high-risk stage IIIB–IV cutaneous melanoma (4 products)
unresectable stage 3 NSCLC (3 products)
unresectable stage IIIA/IIIB NSCLC (3 products)
metastatic ocular melanoma (3 products)
BRAF V600E Mutation-Positive Unresectable or Metastatic Melanoma (3 products)
Stage III melanoma (3 products)
Pediatric melanoma (3 products)
unresectable/metastatic melanoma (3 products)
HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (2 products)
locally advanced low rectal cancer (2 products)
stage III non-small cell lung cancer (2 products)
Resectable NSCLC (2 products)
Advanced NSCLC with EGFR mutation (2 products)
Locally advanced non-small cell lung cancer (2 products)
high grade serous ovarian carcinoma (2 products)
High-grade serous ovarian cancer (HGSOC) (2 products)
Triple-negative breast cancer (2 products)
recurrent or metastatic head and neck squamous cell carcinoma (2 products)
advanced-stage, anti-PD1/PD-L1 relapsed/refractory solid tumors (2 products)
urothelial carcinoma (2 products)
Platinum-sensitive recurrent ovarian carcinoma (2 products)
glioblastoma (2 products)
Uveal melanoma (2 products)
stage IV metastatic melanoma (2 products)
melanoma or lung cancer with autoimmune disease (2 products)
melanoma or lung cancer without autoimmune disease (2 products)
mucosal melanoma (2 products)
stage IV NSCLC (2 products)
advanced NSCLC and melanoma (2 products)
platinum-resistant/refractory epithelial ovarian cancer (2 products)
biliary tract cancer (1 products)
Liver metastases (1 products)
adenocarcinoma of small intestine (1 products)
early-stage colon cancer (1 products)
localized gastric adenocarcinoma (1 products)
Resectable gastric carcinoma (1 products)
Advanced or metastatic gastrointestinal cancers (colorectal, gastric, gastroesophageal) (1 products)
Gastric Cancer (1 products)
locally advanced pancreatic cancer (1 products)
HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma (1 products)
Locally Advanced Gastric Cancer (1 products)
CLDN18.2+, HER2-, LA unresectable or mG/GEJ adenocarcinoma (1 products)
early-stage rectal cancer (1 products)
Gastroesophageal Junction Adenocarcinoma, Gastric Cardia Adenocarcinoma (1 products)
Metastatic gastroesophageal adenocarcinoma (1 products)
dMMR irresectable or metastatic esophagogastric cancer adenocarcinoma (1 products)
RAS wild-type metastatic colorectal cancer (1 products)
Stage 4 Colorectal Cancer (1 products)
Platinum-resistant recurrent ovarian carcinoma (1 products)
locally advanced colon cancer (1 products)
ROS1-rearranged NSCLC (1 products)
stage I/II unresectable NSCLC (1 products)
Ovarian Cancer (1 products)
Advanced Epithelial Ovarian Cancer (1 products)
Locally advanced squamous cell carcinoma of the head and neck (1 products)
MMRd recurrent/metastatic endometrial cancer (1 products)
head and neck cancer (1 products)
Unresectable stage III/IV melanoma (1 products)
non-small lung cancer (1 products)
Advanced solid tumors (ovarian, prostate, breast cancer) (1 products)
recurrent endometrial cancer or ovarian cancer (1 products)
advanced and refractory melanoma (1 products)
Lung cancer (1 products)
advanced malignancies (1 products)
resectable stage II - III non-small cell lung cancer (1 products)
resectable squamous non-small cell lung cancer (1 products)
Melanoma and Merkel Cell Carcinoma (1 products)
Head and neck cancers (1 products)
Unresectable stage III non-small cell lung cancer (1 products)
Non-Small Cell Lung Cancer (1 products)
Unresectable stage IIIB-IV melanoma (1 products)
advanced urothelial carcinoma (1 products)
clinical stages IIIB-IIID melanoma (1 products)
Pregnancy-associated melanoma (1 products)
Prostate cancer (1 products)
recurrent low-grade serous ovarian cancer (1 products)
Low-grade serous ovarian cancer (1 products)
advanced acral lentiginous melanoma (1 products)
relapsed/refractory NSCLC (1 products)
Localized Resectable Tumor, MSI/dMMR or EBV-positive Gastric Cancers (1 products)
Advanced Gastroesophageal Adenocarcinoma (1 products)
Ipilimumab-Naive Melanoma (1 products)
HNSCC (1 products)
Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology (1 products)
Stage I NSCLC (1 products)
Advanced non-small cell lung cancer with actionable driver oncogenes (1 products)
resectable stage IIIA NSCLC (1 products)
Advanced/metastatic NSCLC wild-type for EGFR, ALK and ROS1 (1 products)
KRAS G12C-mutated NSCLC (1 products)
KRAS G12C wild-type NSCLC (1 products)
Advanced acral and mucosal melanoma (1 products)
resected high-risk stage III/IV cutaneous melanoma (1 products)
Advanced NSCLC and HNSCC (1 products)
stage IIIA melanoma (1 products)
Advanced Solid Tumors with DNA Damage Response Gene Aberrations (1 products)
Newly diagnosed glioblastoma or anaplastic astrocytoma (1 products)
stage III/IV resectable melanoma (1 products)
BRAF-mutant melanoma (1 products)
advanced non-acral cutaneous melanoma (1 products)
acral melanoma (1 products)
high-risk stage IIIB-IV melanoma (1 products)
Unresectable hepatocellular carcinoma (1 products)
leiomyosarcoma (1 products)
Loading...

6 drugs

27 abstracts

Abstract
Molecular profiling after short-term preoperative endocrine therapy to identify oestrogen receptor positive (ER+)/HER2+ early breast tumours with favourable prognosis.
Org: Institute of Cancer Research, London, United Kingdom, Royal Marsden Hospital, London, United Kingdom, The Institute of Cancer Research, London, United Kingdom, The Institue of Cancer Research, London, United Kingdom, The Institute of Cancer Research, Sutton, United Kingdom,
Abstract
The prevalence of RCTs in PARP and immune-checkpoint blockade combination trials: An appraisal of clinical evidence generation in oncology.
Org: Beth Israel Deaconess Medical Center, Boston, MA, Cancer Research Institute, New York City, NY, New York, NY,
Abstract
Use of immunotherapy with check point inhibitors in soft tissue sarcoma: Analysis from single institution.
Org: University of Louisville, James Graham Brown Cancer Center,
Abstract
Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS).
Org: Columbia University - Mailman School of Public Health, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Division of Hematology Oncology, UPMC Hillman Cancer Center/University of Pittsburgh, Division of Medical Oncology, Mayo Clinic,
Abstract
A phase II study of anlotinib and an anti-PDL1 antibody in patients with alveolar soft part sarcoma: Results of expansion cohorts.
Org: Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China,
Abstract
Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes.
Org: Massachusetts General Hospital, Brigham and Women's Hospital, Newton,
Abstract
Variation in FOLFOX, FOLFIRI, and FOLFOXIRI effects on CD8+ T cell and PDL1 levels in MSS CRC patients.
Org: Caris Life Sciences, Irving, TX, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, University of Southern California/Norris Comprehensive Cancer Center,
Abstract
Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study.
Org: Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Department of Breast Surgery, Kyorin University School of Medicine/Saitama Medical Center, Tokyo, Japan, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Prospective evaluation of pathologic response with neoadjuvant chemo-immunotherapy in metaplastic breast cancer.
Org: Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering - Breast and Imaging Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.
Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Maryland Capital Region, Caris Life Sciences, Irving, TX, Hoag Memor Hosp, University of Kansas Cancer Center, Kansas City, KS,
Abstract
Telemedicine-supervised cancer therapy for patients with an aggressive lymphoma and metastatic lung cancer in the U.S. Veterans Affairs National TeleOncology Service.
Org: Durham VA Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, VA Salt Lake City Health Care, VHA National Oncology Program Office, University of Utah,
Abstract
The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data.
Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Walter & Eliza Hall Institute of Medical Research and Western Health, Melbourne, Australia, Alfred Hospital Melbourne, Monash Cancer Centre, Royal North Shore Hospital, Sydney, Australia,
Abstract
Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in patients with metastatic colorectal cancer (mCRC).
Org: Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Azienda Ospedaliera Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, University of Pisa, Pisa, Italy, University Campus Biomedico,
Abstract
An open-label window of opportunity trial to evaluate the activity of durvalumab and tremelimumab with platinum-based chemotherapy (gemcitabine and cisplatin) in intrahepatic cholangiocarcinoma.
Org: Emory University School of Medicine, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Birmingham, AL, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan,
Abstract
Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population.
Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, Johns Hopkins University Department of Rheumatology, Baltimore, MD, Johns Hopkins University School of Medicine, Baltimore, MD,
Abstract
Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB-IIIA non–small-cell lung cancer (NSCLC).
Org: Xaf Solutions, Pathologists Bio-Medical Laboratories, Luminis Health, Association of Community Cancer Centers (ACCC), Rockville, MD,
Abstract
Evaluation of THEO-260 as a novel oncolytic virus therapy for treating stromal rich tumours.
Org: Department of Surgery and Cancer, Imperial College London, London, United Kingdom, Theolytics, Oxford, United Kingdom, Imperial College London, London, United Kingdom,
Abstract
Analysis of different color unmixing methods for cMET-PDL1-EGFR multiplex assay.
Org: Rochester Regional Health System, Santa Clara, CanSino Biologics, Tucson, AZ, Azidus Brasil,
Abstract
Role of immune checkpoint inhibitors in PDL1-negative, low TMB, stable MSI metastatic solid tumours: Single centre study.
Org: HCG Cancer Centre Mumbai, Bangalore Institute of Oncology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Vydehi Institute of Medical Sciences & Research Centre,
Abstract
Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfiLER 02 trial.
Org: Centre Léon-Bérard, Centre Léon Bérard, Centre Oscar Lambret, Institut Claudius Regaud/IUCT-Oncopole, Centre Eugène Marquis,
Abstract
Electronic patient-reported outcomes in a cohort of patients with lung cancer treated in the community with shorter versus longer course PD1/PDL1 therapy.
Org: Advicenne Pharma, Canopy Growth, Highlands Oncology Group, Northwest Medical Specialties, CSNF,
Abstract
Prevalence of EGFR and PDL1 testing in a population-based lung cancer surgical resection cohort from 2018-2022.
Org: University of Memphis, School of Public Health, Fudan University, Memphis, TN, Baptist Cancer Center, Memphis, TN, Multidisciplinary Thoracic Oncology Department,
Drug
PD-L1